FASN and hypertriglyceridemia: Despite promising target engagement, central-enzyme inhibition (e.g., ACC/FASN) can trigger compensatory pathways and, in some settings, hypertriglyceridemia; nuclear-receptor agonism shows isoform- and tissue-specific actions with class-dependent safety trade-offs; and species differences complicate extrapolation from preclinical models.